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Abstract: The peer-reviewed marine pharmacology literature from 2009 to 2011 is 
presented in this review, following the format used in the 1998–2008 reviews of this series. 
The pharmacology of structurally-characterized compounds isolated from marine animals, 
algae, fungi and bacteria is discussed in a comprehensive manner. Antibacterial, antifungal, 
antiprotozoal, antituberculosis, and antiviral pharmacological activities were reported for 
102 marine natural products. Additionally, 60 marine compounds were observed to affect 
the immune and nervous system as well as possess antidiabetic and anti-inflammatory 
effects. Finally, 68 marine metabolites were shown to interact with a variety of receptors 
and molecular targets, and thus will probably contribute to multiple pharmacological 
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classes upon further mechanism of action studies. Marine pharmacology during 2009–2011 
remained a global enterprise, with researchers from 35 countries, and the United States, 
contributing to the preclinical pharmacology of 262 marine compounds which are part of 
the preclinical pharmaceutical pipeline. Continued pharmacological research with marine 
natural products will contribute to enhance the marine pharmaceutical clinical pipeline, 
which in 2013 consisted of 17 marine natural products, analogs or derivatives targeting a 
limited number of disease categories. 
Keywords: drug; marine; chemical; metabolite; natural; product; pharmacology; 
pharmaceutical; review; toxicology 
 
1. Introduction 
The current article presents a systematic review of the preclinical pharmacology of the marine 
natural products literature in 2009–2011, with a similar format to previous reviews [1–7], and which 





. We have limited this review to the peer-reviewed literature that reported 
bioactivity or pharmacology of structurally characterized marine chemicals, and have continued to use 
a modification of Schmitz’s chemical classification [8] to assign marine structures to six major 
chemical classes, namely, polyketides, terpenes, peptides, alkaloids, shikimates, and sugars. The 
preclinical antibacterial, antifungal, antiprotozoal, antituberculosis, and antiviral pharmacology of 
marine chemicals is presented in Table 1, with the corresponding structures shown in Figure 1. Marine 
compounds that affect the immune and nervous systems, as well as those with antidiabetic and  
anti-inflammatory effects are shown in Table 2, with their corresponding structures presented in  
Figure 2. Finally, marine compounds that have been demonstrated to affect a wide variety of cellular 
and molecular targets are exhibited in Table 3, and their structures presented in Figure 3. Several 
publications during 2009–2011 described extracts or as yet structurally uncharacterized marine 
compounds, and although they have been excluded from the current review, they certainly deserve 
further investigation because they report novel and interesting in vitro or in vivo preclinical 
pharmacology: antimicrobial and antistaphylococcal biofilm activity of three 5-kDa peptides isolated 
from coelomocyte effector cells of the sea urchin Paracentrotus lividus that could benefit patients with 
medical device-associated infections [9]; an antibacterial polyunsaturated fatty acid, eicosapentanoic 
acid, isolated from extracts of the marine diatom Phaeodactylum tricornutum with activity against a 
range of Gram-positive and Gram-negative bacteria, including multidrug-resistant Staphyloccus  
aureus [10]; potent anticoagulant activity of sulfated polysaccharides isolated from the Brazilian 
brown seaweed Dictyota cervicornis, which was close to that of clinically used low molecular weight 
heparin [11]; potent anticoagulant activity of a sulfated polysaccharide isolated from the Chinese 
green seaweed Monostroma latissimum by a mechanism involving thrombin inhibition in the presence 
of heparin cofactor II [12]; in vitro antileishmanial activity of dichloromethane extracts of a Tunisian 
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sponge Sarcotragus sp., which demonstrated concomitant morphological alterations of Leishmania major 
promastigotes in vitro [13]; in vivo and in vitro antifilarial activity of the marine sponge Haliclona exigua 
extracts against adult nematode Brugia malayi, a parasite that may cause lymphatic filariasis [14]; 
significant nontoxic and anti-herpes simplex virus HSV-1 and HSV-2 activity in sulfated polysaccharide 
extracts isolated from four species of red and brown marine algae from New Zealand [15]; anti-herpes 
simplex virus HSV-1 activity in high molecular weight exopolysaccharides purified from the French 
marine sponge Celtodoryx girardae and its symbiotic bacteria [16]; anti-inflammatory activity of the 
crude extracts and fractions of the Mediterranean sponge Spongia officinalis in the in vivo rat 
carrageenan-induced paw edema assay [17]; in vivo anti-inflammatory activity in polyphenolic extracts 
from the red alga Laurencia undulata resulting in significant inhibition of asthmatic reactions [18];  
in vitro anti-inflammatory effect in an ethanolic extract from the brown alga Ishige okamurae via 
inhibition of NF-κB transcription factor [19]; induction of oxidative death in a human glioma cell line 
through a caspase-9 apoptotic pathway by extracts from the marine sponge Polymastia janeirensis [20]; 
apoptotic activity in extracts from the marine diatom Cocconeis scutellum associated with activation of 
caspases-8 and -3 in human breast cancer lines [21]; human neutrophil anti-elastase activity of purified 
sulfated polysaccharides from the red alga Delesseria sanguinea [22]; high antioxidant activity in 
methanolic extracts of the Korean red alga Polysiphonia morrowii that protected against hydroxyl 
radical-induced DNA damage in vitro [23]; antioxidant activity in phenolic compounds from the 
marine alga Halimeda monile that protected against chemically induced rat liver injury in vivo [24]; 
significant antioxidant properties of polysaccharides from a marine fungus Penicillium sp. F23-2 
against superoxide and hydroxyl radicals [25]; in vitro antioxidant activities of acetylated, phosphorylated 
and benzoylated derivatives of the marine red alga Porphyra haitanensis phorphyran [26]; acceleration 
of skin wound healing by amino acids isolated from the mollusc Rapana venosa suggesting a possible 
therapeutic use in skin burns [27]; neuroprotective effects in extracts of the South Indian green 
seaweed Ulva reticulata that inhibited both acetyl-and butyryl-cholinesterases, and was comparable to 
agents currently approved for Alzheimer’s disease treatment [28]. 
2. Marine Compounds with Antibacterial, Antifungal, Antiprotozoal, Antituberculosis, and 
Antiviral Activities 
Table 1 presents the 2009–2011 preclinical pharmacological research on the antibacterial, 
antifungal, antiprotozoal, antituberculosis, and antiviral activities of the marine natural products  
(1–102) shown in Figure 1. 
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Table 1. Marine pharmacology in 2009–2011: Marine compounds with antibacterial, antifungal, antituberculosis, antiviral and other 
antiprotozoal activities. 













Antibacterial chrysophaentin A (1)/alga Shikimate 
f
  
Methicillin-resistant S. aureus 
inhibition 
1.5 μg/mL + 
Inhibit GTPase activity of 
FtsZ 







 Quorum sensing inhibition 9 μg/mL 








Quorum sensing inhibition 100 μM 
Inhibit homoserine lactone 
receptor LasR 






 M. luteus inhibition 50 μg/mL + Sortase A inhibition S. KOR [32] 
Antibacterial agelasine D (5)/sponge Terpene 
e






















Methicillin-resistant S. aureus 
inhibition 













Methicillin-resistant S. aureus 
inhibition 
2.0–3.9 μg/mL + Undetermined USA [38] 
Antibacterial 



















 S. aureus inhibition 6.25 μg/mL + Undetermined NOR, GBR [41] 
Antibacterial knightol (22)/coral Terpene 
e
 Marine Gram + bacteria inhibition 2–8 μg ++ Undetermined COL [42] 
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Table 1. Cont. 
Antibacterial MC21-B (23)/bacterium Shikimate 
f
 
Methicillin-resistant S. aureus 
inhibition 
1–4 μg/mL + Undetermined JPN [43] 
Antibacterial 





Methicillin-resistant S. aureus 
inhibition 







Vancomycin-resistant E. faecium 
inhibition 







Methicillin-resistant S. aureus 
inhibition 








Methicillin-resistant S. aureus 
inhibition 






 S. aureus inhibition 2.9–4.5 μM Undetermined CAN, COL [48] 
Antibacterial 

























C. albicans & S. cerevisiae 
inhibition 
ND 























 S. cerevisiae inhibition 8 μg/mL + Undetermined AUS [54] 
Antifungal 
marmoratoside A &  
17-hydroxyimpatienside 
A (38,39)/sea cucumber 
Steroid 
glycoside 
e C. albicans inhibition 0.7–11 μg/mL 
+
 Undetermined CHN [55] 
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Table 1. Cont. 
Antifungal saadamycin(40)/bacterium Polyketide 
d
 
C. albicans, Aspergillus & 
Cryptococcus inhibition 
1–5.2 μg/mL + Undetermined EGY [56] 
Antifungal 




 C. albicans inhibition 1–5 μg/disk ++ Undetermined ITA,USA [57] 
Antimalarial plakortin (43)/sponge Polyketide 
d
 
P. falciparum D10 & W2 strain 
inhibition 







P. falciparum FcB1 strain 
inhibition 










P. falciparum FcB1 strain 
inhibition 







P. falciparum 3D7 strain 
inhibition 
0.5–2.9 μM Undetermined FJI, USA [36] 
Antimalarial 





P. falciparum 3D7 strain 
inhibition 







P. falciparum Dd2 & 3D7 strain 
inhibition 
3.5–5.4 μM Undetermined AUS [62] 
Antimalarial 



















P. falciparum W2 strain 
inhibition 







P. falciparum W2 strain 
inhibition 
8.4 μM Undetermined PAN, USA [65] 
Antimalarial gracilioether B (56)/sponge Polyketide 
d







 P. falciparum K1 strain inhibition 0.94 μM Undetermined THAI [67] 
Antimalarial 





P. falciparum NF54 strain 
inhibition 










P. falciparum W2 strain 
inhibition 
2.33 μM Undetermined ITA [69] 
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P. falciparum 3D7 strain 
inhibition 
0.87 μM Undetermined AUS [72] 
Antiprotozoal 




 L amazonensis inhibition 2–12 μg/mL 









L. infantum, T. brucei brucei &  
T. cruzi inhibition 
0.093–0.43 μg/mL Undetermined BEL, NOR [74] 
Antiprotozoal 










 T. brucei brucei inhibition 1.1 μM Undetermined AUS [76] 
Antiprotozoal 






L. donovani & T. brucei 
rhodesiense inhibition 





L. variegata SQDG’s  
(74–76)/alga 
Glycolipid 
E. histolytica & T. vaginalis 
inhibition 












 T. brucei brucei inhibition 2 µg/mL Undetermined USA [79] 
Antiprotozoal 




 Leishmania sp. inhibition 2–3.6 µM Undetermined USA [80] 
Antiprotozoal 





L. donovani & T. brucei 
rhodesiense inhibition 
















L. major & T. brucei brucei 
inhibition 
0.0032–0.11 μM Undetermined GER,USA [83] 
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Table 1. Cont. 
Antituberculosis hymenidin (87)/sponge Alkaloid 
f
 M. tuberculosis H37Rv inhibition 6.1 μg/mL + Undetermined USA [84] 
Antituberculosis 





M. tuberculosis H37Rv strain 
inhibition 









 M. tuberculosis H37Rv inhibition 7.5 μg/mL + Undetermined USA [71] 
Antiviral 







2.6–3.7 μM Undetermined TWN [86] 
Antiviral 















Human herpes simplex virus-1 
inhibition 
1 μM * 
Early ICPO gene transcription 
inhibited 
USA [88] 
Antiviral xiamycin (96)/bacterium Alkaloid 
f
  Inhibition of HIV-1 infection 7.2 μg/mL * 
Selective inhibition of CCR5 
tropic HIV 







Inhibition of HIV-1 IIIB 
replication 
0.2–7.0 μM 
Binding to Vif, APOBEC3G  
& gp41 
DEU, CHN [90] 
Antiviral 





Inhibition of HIV-1 infectivity 
assay 
1.9 μg/mL Undetermined ITA, USA [57] 
a Organism, Kingdom Animalia: ascidian (Phylum Chordata), bryozoa (Phylum Bryozoa), coral (Phylum Cnidaria), sea cucumber (Phylum Echinodermata), sponge (Phylum Porifera); 
Kingdom Monera: bacterium (Phylum Cyanobacteria); Kingdom Fungi: fungus; Kingdom Plantae: alga; b IC50: concentration of a compound required for 50% inhibition in vitro,  
*: estimated IC50; ND: not determined; 
+MIC: minimum inhibitory concentration; ++MID: minimum inhibitory concentration per disk; b MMOA: molecular mechanism of action; c Country: 
AUS: Australia; BEL: Belgium; BRA: Brazil; CAN: Canada; CHE: Switzerland; CHN: China; COL: Colombia; CUB: Cuba; DEU: Germany; EGY: Egypt; FJI: Fiji; FRA: France; GBR: 
United Kingdom; ITA: Italy; JPN: Japan; MEX: Mexico; NCL: New Caledonia; NLD: The Netherlands; NOR: Norway; NZL: New Zealand; PAN: Panama; SGP: Singapore; ZAF: S. 
Africa; S. KOR: South Korea; THAI: Thailand; TWN: Taiwan; UK: United Kingdom; Chemistry: d Polyketide; e Terpene; f Nitrogen-containing compound; g Polysaccharide, modified as in 
the text; h Named as sulfites in the original paper. 
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Figure 1. Marine pharmacology in 2009–2011: Marine compounds with antibacterial, 
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marmoratoside A (38)  R1 =  R2 = H
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Figure 1. Cont. 
































































norbatzelladine A (45)  n = 7


































subereaphenol K methyl ester (44)
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lagunamide A (58) R = 













3,4-dihydro-manzamine J N-oxide (61)
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SQDG analog (74)  R1 = palmitoyl  R2 = myristoyl
SQDG analog (75)  R1 = palmitoyl  R2 = palmitoyl












Mar. Drugs 2013, 11 2525 
 
 










norselic acid A (78) R = H
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trichoderin A (88)  R1 =                               R2 = Me
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baculiferin I (97)  R1 = SO3H, R2 = R3 = H







baculiferin L (99) R = H

























celebeside A (101)  R1 = PO3H2, R2 = C2H5 



















2.1. Antibacterial Activity 
During 2009–2011, 35 studies reported antibacterial marine natural products isolated from a 
diverse group of marine bacteria, ascidians, bryozoans, sponges, soft corals and algae, a persistent 
effort on which we have reported previously [7], and which continues to contribute to the global health 
challenge posed by drug-resistant bacteria. 
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Only four papers reported molecular mechanism of action studies with marine antimicrobial 
compounds. Plaza and colleagues investigated bisdiarylbutene macrocycle chrysophaentin A (1)  
from the chrysophyte alga Chrysophaeum taylori that potently inhibited Gram positive  
methicillin-resistant Staphylococus aureus (minimum inhibitory concentration [MIC]50 = 1.5 μg/mL) 
and vancomycin-resistant Enterococcus faecium (MIC50 = 2.9 μg/mL) by binding and inhibiting 
GTPase activity of the essential bacterial cell division protein FtsZ [29]. Two studies contributed to the 
ongoing search of quorum sensing antagonists as potentially novel antimicrobial drugs: Teasdale and 
colleagues extended the pharmacology of two previously described phenethylamide metabolites 
isolated from a marine Gram positive Halobacillus salinus strain [30]. One of these compounds,  
3-methyl-N-(2′-phenylethyl)-butyramide (2) interfered with quorum sensing-regulated activities (e.g., 
bioluminescence inhibition IC50 = 9 μg/mL) in several Gram negative species. Kwan and colleagues 
isolated a small cyclopropane-containing fatty acid, lyngbyoic acid (3) from the marine 
cyanobacterium Lyngbya cf. majuscula [31] that affected both quorum sensing pathways 
(acylhomoserine lactone receptor LAsR (IC50 = 100 µM) as well as gene expression in Pseudomonas 
aeruginosa. Jeon and colleagues extended the pharmacology of the pyrroloiminoquinone alkaloids of 
the discorhabdin class isolated from the Korean marine sponge Sceptrella sp. [32]. A new alkaloid  
(−)-discorhabdin Z (4), possessing a unique hemiaminal group, inhibited sortase A (IC50 = 6.5 μM), a 
bacterial transpeptidase that has been shown to covalently attach proteins to the bacterial cell wall and 
has become an important antimicrobial target. 
As shown in Table 1 and Figure 1, several marine chemicals, some of them novel, were reported to 
exhibit antibacterial activity with MICs < 10 μg/mL or 10 μM against several bacterial strains, although 
no mechanism of action studies were reported for these compounds: a new alkaloid agelasine D (5) 
isolated from the marine sponge Agelas nakamurai collected in Bali, Indonesia [33]; the maleimide 
mixture aqabamycin E (6) discovered in a marine Vibrio sp. growing on the surface of the Red Sea soft 
coral Sinularia polydactyla [34]; two new cyclodepsipeptides, bacillistatins 1 and 2 (7,8) purified from 
cultures of the Chilean bacterium Bacillus silvestris obtained from a crab [35]; new diterpene–benzoate 
macrolides bromophycolides J–Q (9–14) from the Fijian red alga Callophycus serratus [36]; a novel 
benzoxazole antibiotic caboxamycin (15) produced by the deep-sea Streptomyces sp. NTK 937 isolated 
in the Canary Basin [37]; a brominated polyphenyl ether crossbyanol B (16) isolated from the Hawai’ian 
marine cyanobacterium Leptolyngbya crossbyana [38]; three novel pyridoacridine alkaloids (17–19) 
characterized from the Mediterranean ascidian Cystodytes dellechiajei [39]; the previously-described 
Fijian Cymbastela hooperi diterpene isonitrile (20) recently re-evaluated [40]; a novel alkaloid 
eusynstyelamide F (21), isolated from an Arctic bryozoan Tegella cf. spitzbergensis [41]; a novel 
cembranoid diterpene, knightol (22), found in the Colombian gorgonian octocoral Eunicea knighti [42]; 
the novel antibiotic MC21-B (23) produced by the marine bacterium Pseudoalteromonas phenolica  
O-BC-30T [43]; a novel long-chain 2H-azirine 2-carboxylic acid, motualevic acid F (24), described from 
a Fijian marine sponge Siliquariaspongia sp. [44]; the thiopeptide TP-1161 (25), identified in a 
Norwegian marine-sediment derived Gram positive Nocardiopsis sp. bacterium [45]; two novel α-pyrone 
macrolides neurymenolides A and B (26, 27) isolated from the Fijian red alga Neurymenia  
fraxinifolia [46]; two polybrominated metabolites (28, 29) from a Hawai’ian marine bacterium 
Pseudoalteromonas sp. found on the surface of a nudibranch [47]; pseudopterosin U (30) discovered in 
the Caribbean octocoral Pseudopterogorgia elisabethae [48]; 5-bromo-8-methoxy-1-methyl-β-carboline 
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(31), an alkaloid isolated from the New Zealand marine bryozoan Pterocella vesiculosa [49]; a new 
rifamycin antibiotic, salinisporamycin (32), purified from a culture of the Micronesian marine 
actinomycete Salinispora arenicora YM23-082 [50]; a novel bioactive alkaloid, synoxazolidinone A 
(33), discovered in the sub-Arctic Norwegian ascidian Synoicum pulmonaria [51]. 
Furthermore, during 2009–2011, several marine natural products were noted to have MIC or IC50 
ranging from 10 to 50 μg/mL, or 10–50 μM, respectively, and thus because of their lower antibacterial 
potency were excluded from Table 1 and Figure 1: a novel casbane diterpenoid 10-hydroxydepressin 
(MIC = 17 μg/mL) from the Hainan soft coral Sinularia depressa [91]; a novel guai-2-en-10α-methyl 
methanoate from the marine alga Ulva fasciata (MIC = 25–30 μg/mL) [92]; a novel gymnochrome F 
(MIC = 12.5 μg/mL) from the deep-water crinoid Holopus rangii [93]; several novel fatty acids, 
ieodomycins (MIC = 32–64 μg/mL), from a marine Bacillus sp. [94]; a novel sulfated sesterterpene 
alkaloid 19-oxofasciospongine A from a marine sponge Fasciospongia sp. (MIC = 20 μg/disk) [95]; a 
novel phenalenone derivative (MIC = 24 μM) from the marine-derived fungus Coniothyrium cereale [96]; 
a novel 4,4′-oxybis[3-phenylpropionic acid] from the marine bacterium Bacillus licheniformis  
(IC50 = 50 μg/disk) [97]; a novel sargafuran (MIC = 15 μg/mL) from the marine brown alga Sargassum 
macrocarpum [98]; a novel tetracyclic brominated diterpene (MIC = 32 μg/mL) from the red alga 
Sphaerococcus coronopifolius [99]; and a new bromotyrosine alkaloid tyrokeradine B (MIC = 25 μg/mL) 
from a Verongid marine sponge [100]. 
Finally, during 2009–2011, several publications described novel marine antimicrobial peptides: 
centrocins 1 and 2, two novel dimeric peptides (MIC = 1.3–2.5 μM) from the Norwegian green sea 
urchin Strongylocentrotus droebachiensis [101]; halocyntin and papillosin, two new peptides  
(MIC = 0.75–25 μM) isolated from hemocytes of the Mediterranean ascidian Halocynthia papillosa [102]; 
and hyastatin, a glycine-rich multi-domain peptide (MIC = 0.4–12.5 μM) from hemocytes of the 
Norwegian spider crab Hyas araneus [103]. 
2.2. Antifungal Activity 
Ten studies during 2009–2011 reported on the antifungal activity of several novel marine natural 
products isolated from marine bacteria, sponges and bryozoa, a slight decrease from our last review [7], 
and previous reviews of this series. 
As shown in Table 1, only two reports described antifungal marine chemicals with novel 
mechanisms of action. DiGirolamo and colleagues identified two new sulfated sterols,  
geodisterol-3-O-sulfate (34) and 29-demethylgeodisterol-3-O-sulfate (35), in a marine sponge 
Topsentia sp. [52], which enhanced the activity of the clinically used triazole antifungal agent 
fluconazole by reversing efflux pump-mediated fluconazole resistance in Candida albicans. Nishimura 
and colleagues extended the pharmacology of the bicyclic antifungal dodecapeptide theonellamide F 
(36) previously isolated from a sponge Theonella sp. [53]. Chemical-genomic profiling analysis 
together with detailed subcellular localization studies determined that the antifungal theonellamides 
represent a new class of sterol-binding molecules that induce membrane damage and activate  
Rho1-mediated 1,3-β-D-glucan synthesis.  
Furthermore, as shown in Table 1 and Figure 1 several marine natural products showed significant 
antifungal activity (i.e., MICs that were either less than 10 μg/mL, 10 μM, or 10 μg/disk), although no 
mechanism of action studies were reported in the published articles: the antibacterial alkaloid  
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5-bromo-8-methoxy-1-methyl-β-carboline (31) isolated from the New Zealand marine bryozoan 
Pterocella vesiculosa [49]; a novel linear tetrapeptide citronamide A (37) from the Australian sponge 
Citronia astra [54]; two holostan-type triterpenoid glycosides, marmoratoside A (38) and 17α-hydroxy 
impatienside A (39), from the Chinese sea cucumber Bohadschia marmorata [55]; the polyketide 
saadamycin (40) from an endophytic Streptomyces sp. strain Hedaya 48 isolated from the Egyptian 
sponge Aplysina fistularis [56], and two novel depsipeptides, theopapuamides B & C (41,42), isolated 
from the Indonesian marine sponge Siliquariaspongia mirabilis [57]. Future mechanism of action 
studies with these potent compounds will hopefully characterize their molecular pharmacology. 
Finally, several novel structurally-characterized marine molecules demonstrated MICs or IC50s 
greater than 10 μg/mL or 10 μM, and therefore, because of the reported weaker antifungal activity, have 
been excluded from Table 1 and Figure 1: the maleimide mixture aqabamycin E (6) (MIC = 50 μg/mL) [34]; 
the novel antibacterial alkaloid synoxazolidinone A (33) (MIC = 12.5 μg/mL) [51], and the new 
bromotyrosine tyrokeradine B (MIC = 12.5 μg/mL) [100]. 
These marine compounds may provide novel pharmacological leads thus contributing to the global 
search for clinically useful antifungal agents. 
2.3. Antiprotozoal and Antituberculosis Activity 
As shown in Table 1, during 2009–2011 thirty two studies contributed to novel findings on the 
antiprotozoal and antituberculosis pharmacology of structurally characterized marine natural products, 
a considerable increase from previous 1998–2008 reviews [7]. 
Malaria, which is caused by protozoa from the genus Plasmodium (P. falciparum, P. ovale, P. vivax 
and P. malariae), affects millions of people worldwide. Contributing to the global search for novel 
antimalarial drugs, and as presented in Table 1, twenty six novel marine molecules were shown during 
2009–2011 to possess antimalarial activity, although mechanism of action studies were reported for 
only two compounds. Taglialatela-Scafati and colleagues extended the molecular pharmacology of 
plakortin (43), isolated from the Caribbean marine sponge Plakortis simplex, which potently inhibited  
CQ-resistant strains of Plasmodium falciparum [58]. Plakortin was observed to give rise to toxic 
carbon radicals which were ultimately “responsible for subsequent reactions leading to Plasmodium 
death”. Lebouvier and colleagues reported that the homogentisic acid derivative 44 from a Vanuatu 
marine sponge Pseudoceratina sp. was moderately active in vitro against FcB1 P. falciparum strain, 
while concomitantly inhibiting the specific protein kinase pfnek-1 of the parasite (IC50 = 1.8 μM). 
Thus, compound 44 “could serve as a model for the development of new pfnek-1 inhibitors” [59]. 
Potent (<2 µM) to moderate (>2–10 µM) antimalarial activity was reported for 24 marine natural 
products. Laville and colleagues isolated several novel guanidine batzelladine alkaloids (45–48) from 
the Caribbean marine sponge Monanchora arbuscula, which showed potent antimalarial activity 
against the human malaria parasite Plasmodium falciparum strain FcB1 (IC50 = 0.2–0.9 μM) [60]. 
Lane and colleagues characterized new diterpene–benzoate macrolides bromophycolides J, M, N, O, P 
and Q (9–14) from the Fijian red alga Callophycus serratus with potent antimalarial activity against  
P. falciparum (IC50 = 0.5–2.9 μM) [36]. Furthermore, Lin and colleagues isolated bromophycolides R, 
S and U (49–51) from the same Fijian red alga Callophycus serratus with potent antimalarial activity 
(IC50 = 0.9–2.1 μM) against P. falciparum [61]. Davis and colleagues identified a novel β-carboline 
alkaloid, (+)-7-bromotrypargine (52), from an Australian marine sponge Ancorina sp. with  
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moderate antimalarial activity (IC50 = 3.5–5.4 μM) against both chloroquine resistant (Dd2) and  
chloroquine-sensistive (3D7) P. falciparum strains [62]. Wright and colleagues reported a diterpene 
formamide (53) from the tropical marine sponge Cyambastela hooperi that had moderate to potent 
activity (IC50 = 4.3 ng/mL and 0.5 μg/mL) against P. falciparum strains FCR3F86, W2 and D6 [40,63]. 
Jiménez-Romero and colleagues contributed a novel five-membered-ring polyketide endoperoxide 
epiplakinidioic acid (54) from the Puerto Rican sponge Plakortis halichondrioides that was potent 
(IC50 = 0.3 μg/mL) against the W2 chloroquinone-resistant strain of P. falciparum [64]. Linington and 
colleagues purified a novel linear peptide, gallinamide A (55), from a cyanobacterium Schizothrix sp. 
with moderate antimalarial activity (IC50 = 8.4 μM) against chloroquine-resistant P. falciparum, yet 
with a structure that might become an “attractive foundation for further SAR investigations” [65]. 
Ueoka and colleagues investigated a new polyketide, gracilioether B (56), from the Japanese marine 
sponge Agelas gracilis that was potent (IC50 = 0.5 µg/mL) against P. falciparum strain ItG [66]. 
Wattanapiromsakul and colleagues isolated a new isocyanoditerpene, 8-isocyanoamphilecta-11 (20), 
15-diene (57), from a Thai sponge Ciocalapata sp. with potent antimalarial activity (IC50 = 0.98 μM) 
against P. falciparum chloroquine-resistant strain K1 [67]. Tripathi and colleagues found two new 
cyclic depsipeptides, lagunamides A (58) and B (59), from the Singaporean marine cyanobacterium 
Lyngbya majuscula with potent antimalarial activity (IC50 = 0.19–0.91 μM) against the drug-sensitive 
NF54 P. falciparum strain [68]. Fattorusso and colleagues discovered that a new endoperoxyketal, 
manadoperoxide C (60), from the Indonesian sponge Plakortis cf. simplex, had moderate in vitro 
antiplasmodial activity (IC50 = 2.3 μM) against the W2 chloroquinone-resistant strain of P. falciparum 
as well as provided further insight into “the structure activity relationships of simple 1,2-dioxane 
antimalarials” [69]. Yamada and colleagues identified a novel alkaloid 3,4-dihydro-manzamine J  
N-oxide (61) from an Okinawan marine sponge Amphimedon sp. with potent in vitro antiplasmodial 
activity (IC50 = 0.58 μg/mL) against the K1 strain of P. falciparum [70]. Wei and colleagues extracted 
a new tetracyclic bis-piperidine alkaloid, neopetrosiamine A (62), from the Puerto Rican marine 
sponge Neopetrosia proxima with moderate antiplasmodial activity (IC50 = 2.3 μM) against  
P. falciparum and low concomitant cytotoxicity to Vero cells [71]. Yang and colleagues extended the 
pharmacology of the known bromotyrosine alkaloid psammaplysin F (63) from an Australian marine 
sponge Hyattella sp. by reporting potent inhibition (IC50 = 0.87–1.4 μM) of P. falciparum 3D7 and 
Dd2 strains [72]. 
Eighteen marine compounds were reported to possess activity against other protozoa thus 
contributing to the ongoing global search for novel agents for the so-called neglected diseases, namely 
leishmaniasis (caused by several species of the genus Leishmania), amebiasis, trichomoniasis, African 
sleeping sickness (caused by Trypanosoma brucei rhodesiense and Trypanosoma brucei gambiense) 
and American sleeping sickness or Chagas disease (caused by Trypanosoma cruzi). Dos Santos and 
colleagues reported that a 4-acetoxydolastane diterpene (64) isolated from the Brazilian brown alga 
Canistrocarpus cervicornis [73] dose-dependently inhibited promastigote, axenic amastigote and 
intracellular amastigote forms of Leishmania amazonensis (IC50 = 2.0, 12.0 and 4.0 μg/mL, respectively) 
by extensive mitochondrial damage and lipid peroxidation. 
As shown in Table 1 and Figure 1, several marine natural products were characterized to exhibit 
antiprotozoal activity, although the mechanism of action of these compounds remains undetermined. 
Vik and colleagues completed a comprehensive screening of agelasine terpene analogs from a marine 
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sponge Agelas sp. and reported that four agelasine analogs (65–68) potently inhibited Leishmania 
infantum, T. brucei brucei and T. cruzi (IC50 = 0.093–0.11; 0.11–0.23; 0.11–0.43 μg/mL, respectively) 
with low concomitant cytotoxicity, suggesting they could become novel leads for design of “potent and 
selective drugs” [74]. Sanchez and colleagues found two novel linear lipopeptides, almiramides B and 
C (69,70), from the marine cyanobacterium Lyngbya majuscula that inhibited the protozoan  
parasite Leishmania donovani (IC50 = 1.9–2.4 μM) with minimal cytotoxicity towards Vero cells  
(IC50 = 33.1–52.3 μM) [75]. Davis and colleagues investigated a new brominated alkaloid, 
convolutamine I (71), from the bryozoan Amathia tortusa that was highly active towards the parasite 
Trypanosoma brucei brucei (IC50 = 1.1 μM), yet presenting low cytotoxicity in human embryonic 
kidney cells (IC50 = 22.0 μM) [76]. Scala and colleagues completed the first antiprotozoal screening of 
marine bromopyrrole alkaloids isolated from the marine sponges Axinella verrucosa and Agelas dispar 
and determined that longamide B (72) and dibromopalau’amine (73) inhibited Trypanosoma brucei 
rhodesiense (IC50 = 1.53 & 0.46 μg/mL, respectively), and Leishmania donovani (IC50 = 3.85 & 1.09 μg/mL, 
respectively), with low cytotoxicity [77]. Cantillo-Ciau and colleagues isolated two known and one 
novel sulfoquinovosyl diacylglycerols (74–76) from the Mexican tropical brown alga Lobophora variegata 
with high antiprotozoal activity against E. histolytica (IC50 = 3.9 μg/mL) and moderate activity 
towards Trichomonas vaginalis trophozoites (IC50 = 8.0 μg/mL), and with a good selectivity index  
(SI > 10) [78]. Yamada and colleagues characterized a novel alkaloid 3,4-dihydro-manzamine J  
N-oxide (61) from an Okinawan marine sponge Amphimedon sp. which displayed moderate in vitro 
activity against Trypanosoma brucei brucei (IC50 = 0.27 μg/mL) [70]. Rubio and colleagues evaluated 
several known peroxiterpenes as well as a novel (+)-muqubilone B (77) from the Papua New Guinea 
marine sponge Diacarnus bismarckensis shown to inhibit Trypanosoma brucei brucei (IC50 = 2 μg/mL), 
concluding that these marine chemicals could become “therapeutic leads” against T. brucei [79]. Ma 
and colleagues identified novel highly oxidized steroids norselic acids A–E (78–82) isolated from an 
Antarctic marine sponge Crella sp. which moderately inhibited Leishmania sp. (IC50 = 2.0–3.6 μM) [80]. 
Regalado and colleagues reinvestigated the Caribbean sponge Pandaros acanthifolium and discovered 
that among several new steroidal glycosides, both pandaroside G (83) and pandaroside G methyl ester 
(84) potently inhibited the growth of Trypanosoma brucei rhodesiense (IC50 = 0.8 and 0.038 μM, 
respectively), and Leishmania donovani (IC50 = 1.3 and 0.051 μM, respectively) but with rather high 
concomitant cytotoxicity [81]. Feng and colleagues isolated a novel cyclic polyketide peroxide,  
11,12-didehydro-13-oxo-plakortide Q (85), from an Australian marine sponge Plakortis sp. with 
significant activity (IC50 = 0.049 μM) against Trypanosoma brucei brucei [82]. Pimentel-Elardo and 
colleagues reported the isolation of the known cyclic depsipeptide valinomycin (86) from marine 
Streptomyces sp. strains associated with several Croatian marine sponges, and observed significant 
activity against both Trypanosoma brucei brucei (IC50 = 0.0032 μM) and Leishmania major  
(IC50 < 0.11 μM) [83]. 
As shown in Table 1, four novel marine natural products contributed to the global search for novel 
antituberculosis agents, a decrease from our previous reviews [7]. 
Vicente and colleagues extended the pharmacology of the known compound hymenidin (87) from 
the Puerto Rican marine sponge Prosuberites laughlini by demonstrating its antimycobacterial activity 
(MIC = 6.1 μg/mL) against M. tuberculosis H37Rv [84]. Pruksakorn and colleagues isolated three new 
aminolipopeptides, trichoderins A (88), A1 (89) and B (90) from a marine sponge-derived fungus 
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Trichoderma sp. that potently inhibited (MIC = 0.02–2.0 μg/mL) the M. tuberculosis strain H37Rv 
under both aerobic and dormancy-inducing conditions [85]. Wei and colleagues isolated tetracyclic 
bis-piperidine alkaloid neopetrosiamine A (62) from the Puerto Rican marine sponge Neopetrosia 
proxima which inhibited growth (MIC = 7.5 μg/mL) of the pathogenic strain Mycobacterium tuberculosis 
H37Rv [71]. Although all of these studies demonstrate that marine alkaloids and peptides may 
potentially become novel antituberculosis leads, further studies are required to determine the molecular 
pharmacology of these compounds. 
2.4. Antiviral Activity 
As shown in Table 1, three reports were published during 2009–2011 on the antiviral pharmacology 
of novel marine natural products against human cytomegalovirus and herpes simplex virus. Cheng and 
colleagues purified two new diterpenoids, gyrosanols A and B (91,92), and two novel cembranoids, 
lobophynin C and ehrenberoxide B (93,94), from the Taiwanese soft corals Sinularia capillosa and 
Sarcophyton ehrenbergi, respectively, which inhibited the herpes virus-5 or cytomegalovirus (HCMV) 
(IC50 = 2.6–5.8 μM), an interesting preclinical contribution because HCMV infections may be  
life-threatening in immunocompromised patients [86,87]. Palem and colleagues extended the 
pharmacology of the known β-carboline alkaloid manzamine A (95), isolated from an Indo-Pacific 
sponge Acanthostrongylophora sp., by demonstrating the compound inhibited HSV-1 infection (apparent 
IC50 = 1 μM) in rabbit corneal cells by affecting viral immediate-early gene transcription [88]. 
Three articles reported preclinical pharmacology of marine compounds active against the human 
immunodeficiency virus type-1 (HIV-1), the causative agent of the acquired immunodeficiency disease 
syndrome (AIDS), a decrease from our previous review [7]. Ding and colleagues investigated the 
novel pentacyclic indolosesquiterpene xiamycin (96) isolated from the Streptomyces sp. GT2002/1503 
bacterium and demonstrated selective inhibition against macrophage and T cell β-chemokine receptor 
CCR5 (5) tropic HIV-infection (estimated IC50 = 7.2 μg/mL), with no effect against α-chemokine 
receptor CXCR4 (X4) tropic HIV [89]. Fan and colleagues isolated several DOPA-derived pyrrole 
alkaloids, baculiferins I, J, L and M (97–100), from the Chinese marine sponge Iotrochota baculifera, 
which were found to be potent inhibitors of HIV-1 IIIB (IC50 = 0.2–7.0 μM) by binding to the HIV 
target proteins Vif, APOBEC3G, and gp41 in an as yet undetermined mechanism [90]. Plaza and 
colleagues isolated several new cyclic depsipeptides from the Indonesian marine sponge 
Siliquariaspongia mirabilis including celebesides A and C (101–102), which inhibited HIV-1 in an 
infectivity assay (IC50 = 1.9 ± 0.4 μg/mL), thus correlating the anti-HIV activity of these compounds 
with the presence of phosphoserine [57]. 
3. Marine Compounds with Antidiabetic and Anti-Inflammatory Activity, and Affecting the 
Immune and Nervous System 
Table 2 presents the preclinical pharmacology of marine chemicals (103–162) which demonstrated 
antidiabetic and anti-inflammatory activity, as well as affected the immune and nervous system, and 
whose structures are shown in Figure 2. 
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Table 2. Marine pharmacology in 2009–2011: Marine compounds with antidiabetic and anti-inflammatory activity; and affecting the immune 
and nervous system. 


















100 mg/kg * 
α-glucosidase and  
α-amylase inhibition 
S. KOR [104] 
Antidiabetic dysidine (104)/sponge Terpene 
f
 Insulin signaling and glucose uptake 6.7 μM hPTP1b inhibition CHN [105,106] 
Anti-inflammatory 





Modulation of LPS-activated murine  
macrophages in vitro 
3–10 μM * 
Nitric oxide and 
PGE2 inhibition 
USA [107] 
Anti-inflammatory callysterol (107)/sponge Steroid 
f




Anti-inflammatory capnellene (108)/soft coral Terpene 
f
 
In vivo inhibition of microglia 
activation 
10 mg/kg * 









Modulation of LPS-activated 
microglia in vitro 
7.0 μM TXB2 inhibition USA [110] 
Anti-inflammatory floridosides (110,111)/alga Glycolipid 
Free-radical oxidative stress 
inhibition 










LPS-activated macrophage in vitro 
inhibition 











Anti-inflammatory PFF-A (114)/alga Polyketide 
e
 
LPS-activated macrophage in vitro 
inhibition 
4.7 μM 
iNOS and COX-2 
inhibition 
S. KOR [114] 
Anti-inflammatory 

















Anti-inflammatory tedanol (117)/sponge Terpene 
f
 Murine hind paw oedema inhibition 1 mg/kg * 
iNOS, COX-1 and 
COX-2 inhibition 
ITA [117] 
Anti-inflammatory carijoside A (118)/coral Steroid glycoside 
f
 
Neutrophil superoxide and elastase 
inhibition 
1.8–6.8 μg/mL Undetermined TWN [118] 
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Macrophage COX-2 & iNOS 
expression inhibition 







Macrophage PGE2 & nitric oxide 
inhibition 










Macrophage COX-2 & iNOS 
expression inhibition 
10 μM * Undetermined TWN [121] 
Anti-inflammatory 





Macrophage COX-2 & iNOS 
expression inhibition 
10 μM * Undetermined TWN [122] 
Anti-inflammatory 





Macrophage iNOS expression 
inhibition 
10 μM * Undetermined TWN [123] 
Anti-inflammatory 
klysimplexin sulfoxide 




Macrophage COX-2 & iNOS  
expression inhibition 
10 μM * Undetermined TWN [124] 
Anti-inflammatory 





Macrophage NO release & iNOS 
expression inhibition 
3.8–4.0 μM Undetermined JPN [125] 
Anti-inflammatory 




 Murine hind paw oedema inhibition 0.3 mg/kg * Undetermined FRA, ITA [126] 
Anti-inflammatory 




 Neutrophil superoxide inhibition 0.8–2.5 μM Undetermined MYS, NZL [127] 
Anti-inflammatory 





Macrophage iNOS expression 
inhibition 
10 μM * Undetermined TWN [128] 
Anti-inflammatory 
sarcoehrenosides A & B 
(135,136)/soft coral 
Glycolipid 
Macrophage iNOS expression 
inhibition 
10 μM * Undetermined TWN [129] 
Anti-inflammatory 





Macrophage iNOS expression 
inhibition 
10 μM * Undetermined TWN [130] 
Anti-inflammatory 





Macrophage COX-2 & iNOS  
expression inhibition 
10 μM * Undetermined TWN [131] 
Anti-inflammatory terpioside B (140)/sponge Glycolipid 
Macrophage iNOS expression 
inhibition 
<10 μM * Undetermined ITA [132] 
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Table 2. Cont. 
Immune system 




 T cell antigen presentation inhibition 10 μM * 
Cathepsin E, IL-17 
and IFN-γ inhibition 
USA [133] 
Immune system 





 Dendritic cell activation 10 μM * 
IL-10 and  
Ag-presenting 
activity 
DEU, JPN [134] 
Immune system PFF-A (114)/alga Polyketide 
e
 Basophil IgE receptor inhibition 25 μM * 
Ca
2+
 influx and 
degranulation 
inhibition 




PKS/NRPS Interleukin 5 and 13 Inhibition 1.6–1.8 nM Undetermined USA [136] 
Immune system HCLPS-1 (147)/clam Polysaccharide 
h
 
In vivo & in vitro T and B cell 
activation 
20 mg/kg * Undetermined CHN [137] 





Macrophage phagocytosis inhibition 1 nM * 
TNF-α, MIP-1α & 
MIP-2 inhibition 
ITA [138] 
Nervous system calyculin A (149)/sponge PKS/NRPS 
e
 
Hippocampal neuron neurite 
retraction 












































MEX, USA [142] 
Nervous system xyloketal B (153)/fungus Polyketide 
e
 
Ischemia-induced PC12 cell  
injury inhibition 











4.18 μM Undetermined MEX, USA [144] 
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 Α2B adrenoreceptor agonist 4.2 µM Undetermined AUS [145] 
Nervous system dysideamine (156)/sponge Terpene 
e
 
Hippocampal reactive oxygen 
species inhibition 







α1 & α3 glycine receptor 
potentiation 
0.5 µM * Undetermined AUS [147] 
Nervous system 





Neuronal nitric oxide synthase 
inhibition 















 Human serotonin 5-HT2B binding 505 nM ** Undetermined PHL, USA [150] 
a Organism: Kingdom Animalia: ascidian (Phylum Chordata), coral (Phylum Cnidaria), clam (Phylum Mollusca), fireworm (Phylum Polychaeta), sponge (Phylum Porifera); Kingdom 
Chromalveolata: dinoflagellates (Phylum Dinoflagellata); Kingdom Fungi: fungus; Kingdom Plantae: alga; Kingdom Monera: bacterium; b IC50: concentration of a compound required for 
50% inhibition, *: apparent IC50; **: Ki; ND: not determined; 
c MMOA: molecular mechanism of action, NO: nitric oxide; d Country: AUS: Australia; BRA: Brazil; CHN: China; DEU: 
Germany; EGY: Egypt ; ESP: Spain; FRA: France; IDN: Indonesia; ITA: Italy; JPN: Japan; MEX: Mexico; MYS: Malaysia; NLD: The Netherlands; NZL: New Zealand; PNG: Papua New 
Guinea; PHL: Phillipines; S.KOR: South Korea; TWN: Taiwan; e Chemistry: Polyketide; f Terpene; g Nitrogen-containing compound; h polysaccharide, modified as in the text. 
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Figure 2. Marine pharmacology in 2009–2011: Marine compounds with antidiabetic and  
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3.1. Antidiabetic Activity 
Heo and colleagues extended the pharmacology of diphlorethohydroxycarmalol [DPHC] (103), 
previously isolated from the marine brown alga Ishige okamurae, by showing that DPHC alleviated 
postprandial hyperglycemia in diabetic mice by potent inhibition of both α-glucosidase and α-amylase 
enzymes (IC50 = 0.16 and 0.53 nM, respectively) suggesting a possible use of DPHC “as a 
nutraceutical or functional food for diabetes” [104]. Li and colleagues evaluated the known 
sesquiterpene dysidine (104) from the Hainan marine sponge Dysidea villosa, and revealed that it 
activated the insulin pathway by inhibition of human protein phosphatase 1B (IC50 = 6.70 µM), a well 
characterized drug target for type-II diabetes and obesity treatment, as well as glucose uptake and 
glucose transporter 4 translocation in vitro [105,106]. 
3.2. Anti-Inflammatory Activity 
There was a remarkable increase in marine anti-inflammatory pharmacology research during  
2009–2011. The molecular mechanism of action of several marine natural products, which were shown 
in preclinical pharmacological studies to target neutrophils and macrophages both in vitro and in vivo, 
was reported in several publications. Asolkar and colleagues described two new cyclohexadepsipeptides 
arenamides A and B (105,106), isolated from the Fijian bacterium Salinispora arenicola, that inhibited 
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LPS-induced murine macrophage RAW 264.7 cells PGE2 and NO production in vitro, by  
affecting NFκB signaling activity (IC50 = 3.7 and 1.7 μM, respectively), thus highlighting their  
“anti-inflammatory characteristics” [107]. Three publications yielded potentially novel compounds 
targeting proinflammatory mediators released by activated brain microglia, a macrophage involved in 
neuroinflammation and neurodegeneration [151]: Youssef and colleagues described a new steroid 
callysterol (107) from the Red Sea sponge Callyspongia siphonella, which potently inhibited rat hind 
paw edema with an activity close to cortisone, and also reduced TXB2 release from LPS-activated rat 
brain microglia (apparent IC50 > 10 μM) [108]. Jean and colleagues observed that the sesquiterpene 
capnellene (108) isolated from the Indonesian soft coral Capnella imbricate, attenuated expression of 
inducible cyclooxygenase-2 both in activated microglia in vitro and in vivo, suggesting it might 
contribute to “the search for new therapeutic agents for treatment of neuroinflammatory diseases” [109]. 
Shi and colleagues isolated a new terpene, elisabethin H (109) from the Caribbean gorgonian octocoral 
Pseudopterogorgia elisabethae, which significantly inhibited superoxide anion (O2
–
) generation from  
E. coli LPS activated rat neonatal microglia in vitro (IC50 = 7 μM) [110]. Li and colleagues reported 
that the floridosides (110,111), isolated from the South Korean marine red alga Laurencia undulata, 
possessed significant antioxidant capacity and inhibited the proinflammatory matrix metalloproteinases 
MMP-2 and MMP-9, thus suggesting they might be candidates for further development as natural 
marine antioxidants [111]. Three publications investigated inhibition of pro-inflammatory mediators 
released by activated macrophage cell lines: Malloy and colleagues reported that the lipopeptide 
malyngamide 2 (112) from the Papua New Guinea marine cyanobacterium Lyngbya sordida inhibited 
nitric oxide production in LPS-primed RAW 264.7 macrophage cells (IC50 = 8.0 μM) [112]. In a 
detailed mechanistic study Villa and colleagues investigated the lipopeptide malyngamide F (113) 
from the marine cyanobacterium Lyngbya majuscula showing that it inhibited nitric oxide production 
in LPS-primed RAW 264.7 macrophage cells (IC50 = 7.1 μM) by selectively inhibiting the  
MyD88-dependent pathway of TLR4 and 9, thus potentially becoming a “useful tool” in cellular 
biology [113]. Kim and colleagues extended previous studies with the phlorotannin 
phlorofucofuroeckol A (PFF-A) (114), isolated from the Korean brown alga Ecklonia stolonifera, by 
demonstrating its antioxidant activity was of similar potency to vitamin C, and that it inhibited nitric 
oxide and PGE2 production (apparent IC50 = 5–10 μM) by downregulation of iNOS and COX-2 protein 
expression in LPS-primed RAW 264.7 macrophage cells [114]. Using an in vivo rat colitis model, 
Belmiro and colleagues provided a detailed molecular characterization of the anti-inflammatory 
properties of a dermatan sulfate (115), analog of mammalian heparin, purified from the Brazilian 
ascidian Styela plicata, which at 8 mg/kg per day significantly decreased lymphocyte and macrophage 
recruitment as well as TNF-α, TGF-β, and VEGF production in the inflamed rat colon [115]. Hanif and 
colleagues reported that the highly hydroxylated long-chain sulfate symbiopolyol (116), isolated from 
a symbiotic dinoflagellate of the jellyfish Mastigias papua significantly inhibited (K50 = 6.6 μM) the 
expression of the inducible adhesion vascular cell adhesion molecule-1 which binds to leukocytes 
present in early stages of inflammation, and thus might become a “potential anti-inflammatory  
agent” [116]. Costantino and colleagues reported that tedanol (117), a new brominated and sulfated 
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pimarane diterpene isolated from the Caribbean sponge Tedania ignis, significantly reduced both the 
acute and subchronic phases of carrageenan-induced inflammation at 1 mg/kg with concomitant 
inhibition of both COX-2, iNOS expression and cellular infiltration [117]. 
As shown in Table 2 and in contrast to the marine anti-inflammatory compounds previously 
discussed, while an anti-inflammatory activity and IC50 were reported, the molecular mechanism of 
action remained undetermined for the following marine compounds: carijoside A (118) [118]; 
chabrosterol (119) [119]; coscinolactams (120–122) [120]; durumhemiketalolide C (123) [121]; 
durumolide F (124) [122]; gyrosanolides B and C (125,126) [123]; klysimplexin sulfoxide C  
(127) [124]; L. crassum diterpenes (128,129) [125]; perthamides C and D (130,131) [126]; rossinones 
A and B (132,133) [127]; nebrosteroid I (134) [128]; sarcoehrenosides A and B (135,136) [129]; 
sarcocrassocolides A & B (137,138) [130]; simplexin E (139) [131]; and terpioside B (140) [132]. 
3.3. Marine Compounds with Activity on the Immune System 
In 2009–2011, immune system pharmacology of marine compounds showed a considerable 
decrease from our previous review. 
Kwan and colleagues isolated the linear peptides grassystatins A–C (141–143) from a marine 
cyanobacterium identified as Lyngbya cf. confervoides, demonstrating that the compounds selectively 
inhibited aspartic protease cathepsin E (IC50 = 0.3–0.8 nM) versus cathepsin D, as well as  
antigen-stimulated T cell proliferation, with a concomitant reduction of IL-17 and interferon γ [133]. 
Takei and colleagues reported that the known compounds callyspongidiol (144) and  
14,15-dihydrosiphonodiol (145), isolated from a marine sponge Callyspongia sp., activated both 
functional and phenotypic maturation of human monocyte-derived dendritic cells, as well as higher 
interleukin-10 production by T cells, thus revealing potential use in autoimmune diseases and  
cancer [134]. Shim and colleagues observed that the phloroglucinol derivative phlorofucofuroeckol A 
(PFF-A) (114), purified from the Korean marine seaweed Ecklonia stolonifera, reduced the expression 
of the human basophil FcεR1 receptor (apparent IC50 = 25 µM), as well as intracellular [Ca
2+
]i and 
histamine release, findings which may be relevant for regulation of IgE-mediated allergic  
reactions [135]. Strangman and colleagues discovered novel splenocin B (146) isolated from the 
marine bacterium Streptomyces species strain CNQ431 that displayed potent inhibition of murine 
splenocyte-derived TH2 cytokines interleukin 5 and 13 (IC50 = 1.6–1.8 nM), thus contributing to the 
development of a “splenocin-derived drug” for allergic inflammation [136]. Dai and colleagues 
isolated a water soluble polysaccharide HCLPS-1 (147) from the Chinese pearl-producing mollusc 
Hyriopsis cumingii Lea, which stimulated murine spleen lymphocyte proliferation in vitro and in vivo 
in a concentration-dependent manner (apparent IC50 less than 20 mg/kg), suggesting HCLPS-1 might 
become a “potential natural immunomodulator” upon further pharmacological study [137]. Orsi and 
colleagues contributed to the immunopharmacology of the sulfated dinoflagellate polyether yessotoxin 
(148), by demonstrating that it decreased macrophage phagocytic activity against the fungus Candida 
albicans (apparent IC50 = 1 nM), affected the cytoskeleton by inducing F-actin re-organization, and 
enhanced release of the cytokine TNF-α and chemokines MIP-1α and MIP-2 [138]. 
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3.4. Marine Compounds Affecting the Nervous System 
As shown in Table 2, the nervous system pharmacology of marine natural products in 2009–2011 
involved some areas of neuropharmacology, namely neuronal neurite retraction, neurotransmission 
inhibition, neuronal Ca
2+
 oscillations and free radical inhibition. 
Marine natural products have previously been reported to affect neuritogenesis [7], a process 
required by neurons to respond to the extracellular environment to form synaptic connections. Inutsuka 
and colleagues contributed novel molecular studies on the effect of calyculin A (149) on neurons, 
demonstrating that rapid rat hippocampal neuron neurite retraction (apparent IC50 = 100 mM) induced 
by the toxin was dependent on actin filament polymerization or myosin II motor, yet independent of 
the microtubule polymerization status, and perhaps resulted from dephosphorylation of myosin light 
chain kinase [139]. Sakurada and colleagues reported that the novel Palauan sponge Cribrochalina 
olemda purine (150), which elicited convulsions upon intracerebroventricular injections in mice  
(4 nM/mouse), inhibited GABAergic transmission in hippocampal neurons [140]. Noteworthy was the 
author’s observation that this marine purine was “closely related in structure to endogenous 
neurosignaling molecules and commonly used CNS stimulants”. 
As shown in Table 2, two marine compounds (151,152) identified as part of a drug discovery 
screening program, were shown to inhibit neuronal Ca
2+
 oscillations, a network phenomenon that 
appears to depend on voltage-gated sodium channel activation. Choi and colleagues reported that a 
cyclic depsipeptide hoiamide B (151), isolated from a Papua New Guinean cyanobacteria assemblage 
of Symploca sp. and Oscillatoria cf. sp., stimulated sodium influx (IC50 = 3.9 µM) in murine neuronal 
cells in vitro by putative activation of site 2 on the sodium channel, while suppressing spontaneous 
Ca
2+
 (IC50 = 79.8 nM) with greater potency, thus revealing that hoiamide B may have more than one 
molecular target [141]. Pereira and colleagues contributed a novel marine macrolide palmyrolide A 
(152) isolated from Northern Pacific Palmyra Atoll cyanobacteria assemblages of Leptolyngbya cf. and 
Oscillatoria sp. that inhibited both sodium influx (IC50 = 5.2 µM) in mouse neuroblastoma cells and 
spontaneous Ca
2+
 oscillations (IC50 = 3.7 µM) in primary cultures of murine cerebrocortical neurons, 
“making it an intriguing candidate for further pharmacological exploration” [142]. Zhao and 
colleagues reported that the known compound xyloketal B (153), isolated from the marine mangrove 
fungus Xylaria sp., inhibited ischemia-induced PC12 cell injury (IC50 = 100 µM) by a neuroprotective 
mechanism involving free radical scavenging and reduction of mitochondrial membrane potential and 
superoxide generation, suggesting further development for effective stroke therapy [143]. 
Finally, and as presented in Table 2, during 2009–2011, several other marine compounds were 
reported to affect the nervous system by demonstrating pharmacological activity on Ca
2+
 oscillations, 
several receptors, and neuronal nitric oxide synthase, yet the mechanism of action of these compounds 
remained undetermined: alotamide A (154) [144], (−)-dibromophakellin (155) [145], dysideamine 
(156) [146], ircinialactams (157,158) [147], eusynstyelamides B and C (159,160) [148], nanolobatolide 
(161) [149], and pulicatin A (162) [150]. 
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4. Marine Compounds with Miscellaneous Mechanisms of Action 
Table 3 presents the 2009–2011 preclinical pharmacology of 68 marine compounds (163–226) with 
miscellaneous mechanisms of action, with their respective structures shown in Figure 3. Because 
additional in vitro and in vivo pharmacological data for these compounds remained unpublished, 
assignment of these marine compounds to a particular drug class was not possible. 
As shown in Table 3, the peer-reviewed literature reported a pharmacological activity, an IC50, and 
a molecular mechanism of action for 21 marine natural products: bisebromoamide (163) [152]; 
botryllamides I and J (164,165) [153]; dysidine (104) [106]; Ecklonia cava phlorotannins  
(166,167) [154]; fucophlorethols (168,169) [155]; gonad-stimulating substance (GSS) (170) [156]; 
halichlorine (171) [157]; hoiamide A (172) [158]; hypochromins A and B (173,174) [159]; mycothiazole 
(175) [160]; Mycale sp. pyrroles (176,177) [161]; neocomplanines A and B (178,179) [162]; 
pateamine A (180) [163]; polytheonamide B (181) [164]; and zampanolide (182) [165]. 
In contrast, although a pharmacological activity was described, and an IC50 for inhibition of an 
enzyme or receptor determined, detailed molecular mechanism of action studies were unavailable at 
the time of publication for the following 47 marine compounds included in Table 3: alotaketals A and 
B (183,184) [166]; aquastatin A (185) [167]; australin E (186) [168]; lyngbyastatins 9 & 10  
(187,188) [169]; brunsvicamides A, B and C (189–191) [170]; carteriosulfonic acids A, B and C  
(192–194) [171]; Carteriospongia foliascens sesterterpenoids (195,196) [172]; clavatadines D and E 
(197,198) [173]; fibrosterol sulfates A and B (199,200) [174]; gracilin L (201) [175]; grassystatins A, 
B and C (141–143) [133]; 2-hydroxycircumdatin C (202) [176]; jaspaquinol (203) [177]; largamides 
A, B and C (204–206) [178]; largamide D oxazolidine (207) [179]; Laurencia similis brominated 
metabolites (208,209) [180]; molassamide (210) [181]; myrothenone A (211) [182]; 42-hydroxy-palytoxin 
(212) [183]; plectosphaeroic acids A, B and C (213–215) [184]; puupehenone (216) [177];  
Sinularia numerosa oxylipin (217) [185]; sipholenone E (218) [186]; spartinoxide (219) [187];  
23-nor-spiculoic acid B (220) [188]; tanikolide dimer (221) [189]; tamulamides A and B (222,223) [190]; 
terretonins E and F (224,225) [191]; and tetrangulol methyl ether (226) [192]. 
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In vitro tumor growth 
inhibition 
0.040 μM ERK inhibition JPN [152] 




 Multidrug resistance inhibition 27–41 μM ABCG2 transporter inhibition USA [153] 
dysidine (104)/sponge Terpene 
f
 Insulin pathway activation 10 μM 
Protein tyrosine phosphatase 
1B inhibition 
CHN [106] 
E. cava phlorotannins (166,167)/alga Polyketide 
e
  In vitro antioxidants  





fucophlorethols (168,169)/alga Polyketide 
e
  DPPH radical scavenging 10–14 μM 
Cytochrome P450 CYP1A 
inhibition 
DEU, ISR [155] 
GSS (170)/starfish Peptide 
g
 
Oocyte maturation and 
ovulation 






Inhibition of vascular 
contractility 
3 μM * L-type Ca2+ channel inhibition JPN [157] 
hoiamide A (172)/bacterium Peptide 
g
 
Voltage-gated sodium  
channel activator 
2.3 μM Sodium channel site 2 activator USA [158] 




  Angiogenesis inhibition 13 & 50 μM Tyrosine kinase inhibition JPN [159] 
mycothiazole (175)/sponge PKS/NRPS Angiogenesis inhibition 10 nM * 
Mitochondrial complex 1 
inhibition 
USA [160] 









transport chain inhibition 
USA [161] 




 Murine footpad inflammation ND PKC activation JPN [162] 




 Binding to eukaryotic initiation 
factor 4AIII 
DEU, USA [163] 
polytheonamide B (181)/sponge Peptide 
g
 
Cytotoxic mammalian  
channel formation 
14–29 nM Selectivity towards Cs + cation JPN [164] 
zampanolide (182)/sponge Polyketide 
e
 G2/M cell cycle arrest 8 nM * 
Microtubule bundle formation 
by tubulin polymerization 
NZL [165] 
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Table 3. Cont. 
alotaketals A & B (183,184)/sponge Terpene 
f




aquastatin (185)/fungus Polyketide 
e
  
Protein phosphatase 1B 
inhibition 
0.19 μM Undetermined S. KOR [167] 
australin E (186)/soft coral Terpene 
f
 
Inositol 5-phosphatase SHIP1 
activation 
>100 μM Undetermined CAN [168] 





Elastase and chymotrypsin 
inhibition 
0.2–9.3 μM Undetermined USA [169] * 




 Elastase inhibition 2.0–4.4 μM Undetermined DEU [170] 










Human Ras-converting  
enzyme inhibition 









 Factor XIa inhibition 222 μM * Undetermined AUS [173] 




 Protein Kinase Cζ inhibition 5.6 & 16.4 µM Undetermined PHL, USA [174] 
gracilin L (201)/sponge Terpene 
f
 
EGF-R tyrosine kinase 
inhibition 
<100 μM * Undetermined GBR, LUX [175] 










DPPH radical scavenging 
activity 
9.9 µM Undetermined CHN [176] 
jaspaquinol (203)/sponge Terpene 
f
 5-lipoxygenase inhibition 0.45 µM Undetermined USA [177] 




 Elastase inhibition 0.53–1.41 µM Undetermined USA [178] 
largamide D oxazolidine 
(207)/bacterium 
Peptide 
g Elastase and chymotrypsin 
inhibition 
0.9–1.5 μM Undetermined USA [179] 
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Table 3. Cont. 





Protein phosphatase 1B 
inhibition 
2.7–3 μM Undetermined CAN, CHN [180] 
molassamide (210)/bacterium Peptide 
g
 
Elastase and chymotrypsin 
inhibition 
0.03 & 0.23 μM Undetermined USA [181] 
myrothenone A (211)/fungus Polyketide 
e







 pump inhibition 28 ± 7 nM Undetermined ITA, USA [183] 





Indoleamine 2, 3  
dioxygenase inhibtion 
2 μM * Undetermined CAN [184] 
puupehenone (216)/sponge Terpene 
f 
5-lipoxygenase inhibition 0.68 μM Undetermined USA [177] 




  Angiogenesis inhibition 20–40 μM Undetermined JPN [185] 









spartinoxide (219)/fungus Terpene 
f
 Human elastase inhibition 6.5 μM Undetermined DEU [187] 




  NFκB inhibition 0.47 μM Undetermined VEN, USA [188] 
tanikolide dimer (221)/bacterium Polyketide 
e
  
Human sirtuin type 2 
inhibition 












0.2–2.5 μM Undetermined USA [190] 
terretonins E & F (224,225)/fungus Terpene 
f
 NADH oxidase inhibition 2.9–3.9 μM Undetermined ESP, ITA [191] 







0.16 μM Undetermined USA [192] 
a Organism, Kingdom Animalia: ascidian (Phylum Chordata), fireworm (Phylum Annelida), soft corals (Phylum Cnidaria), starfish ( Phylum Echinodermata), sponge (Phylum Porifera); 
Kingdom Chromalveolata: dinoflagellates; Kingdom Fungi: fungus; Kingdom Plantae: alga; Kingdom Monera: bacterium; b IC50: concentration of a compound required for 50% inhibition  
in vitro; *: estimated IC50; 
c MMOA: molecular mechanism of action; d Country: AUS: Australia; CAN: Canada; CHN: China; DEU: Germany; EGY: Egypt; ESP: Spain; GBR: United 
Kingdom; IDN: Indonesia; ISR: Israel; ITA: Italy; JPN: Japan; LUX: Luxembourg; NZL: New Zealand; NLD: The Netherlands; PHL: Phillipines; PAP: Papua New Guinea; SGP: 
Singapore; S. KOR: South Korea; ESP: Spain; VEN: Venezuela; e Chemistry: Polyketide; f Terpene; g Nitrogen-containing compound; *: Bouillamides A and B are identical with 
lyngbyastatins 9 and 10. See [193]. 
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Figure 3. Marine pharmacology in 2009–2011: Marine compounds with miscellaneous 
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D-Asm - L-Val -  D-Ser -  L-Val - D-Asn - L-Mne -
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5. Reviews on Marine Pharmacology 
Several reviews covering both general and specific areas of marine preclinical pharmacology were 
published during 2009–2011: (a) marine pharmacology and marine pharmaceuticals: a renaissance 
in marine pharmacology: from preclinical curiosity to clinical reality [194]; biologically active marine 
natural products [195]; drug development from marine natural products [196]; biotechnological 
potential of marine natural products [197]; pharmaceuticals from marine natural products: surge or 
ebb? [198]; marine pharmacology in Australia: the Roche Research Institute [199]; the global marine 
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pharmaceutical pipeline in 2010: U.S. Food and Drug Administration-approved compounds and those 
in Phase I, II and III of clinical development [200]; marine drugs from sponge-microbe associations [201]; 
cyanobacteria as an emerging source for drug discovery [202]; marine invertebrates as a future therapeutic 
treasure [203]; biodiversity conservation and marine natural products drug discovery [204]; marine 
invertebrates as a source of guanidines with chemical and pharmacological significance [205]; 
innovations in the field of marine natural products and a new wave of drugs [206]; (b) antimicrobial 
marine pharmacology: antibacterial marine natural products [207]; marine microbes and pharmaceutical 
development [208]; marine microbe-derived antibacterial agents [209]; antimicrobial peptides from 
marine invertebrates [210]; novel anti-infective compounds from marine bacteria [211]; conventional 
and unconventional antimicrobials from fish, marine invertebrates and microalgae [212]; (c) antiviral 
marine pharmacology: antiviral lead compounds from marine sponges [213]; potential anti-HIV agents 
from marine resources [214]; marine compounds and their antiviral activities [215]; marine organisms as 
a therapeutic source against herpes simplex virus infection [216]; (d) antiparasitic, antituberculosis, 
antimalarial and antifungal marine pharmacology: antiparasitic marine invertebrate-derived small 
molecules [217]; marine antileishmanial natural products [218]; antituberculosis leads from marine 
microbial metabolites [219]; antimalarial drug discovery from marine sources between January 2003 and 
December 2008 [220]; antimalarial marine natural products from 2006 to 2008 [221]; antimalarial marine 
compounds [222]; (e) immuno- and anti-inflammatory marine pharmacology: marine natural product 
leads for treatment of inflammation [223]; marine natural products targeting phospholipase A2 [224]; 
marine diterpene glycosides as anti-inflammatory agents [225]; anti-inflammatory compounds from 
marine algae [226]; (f) cardiovascular marine pharmacology: marine-derived angiotensin-I-converting 
enzyme inhibitors [227]; (g) nervous system marine pharmacology: conotoxins as natural products drug 
leads [228]; marine indole alkaloids as new drug leads for depression and anxiety [229]; marine natural 
products and ion channel pharmacology [230]; neuroprotective effects of marine algae [231]; 
conopeptides as novel options for pain management [232]; structure-activity studies with α-conotoxins as 
selective antagonists of nicotinic acetylcholine receptors [233]; (h) miscellaneous molecular targets: 
calyculins and related marine natural products as serine threonine protein phosphatase inhibitors [234]; 
NF-κB inhibition by marine natural products [235]; protein kinase inhibitors from marine sponges [236]. 
6. Conclusions 
The global marine preclinical and clinical pharmaceutical pipelines remain remarkably active one 
year after U.S. Food and Drug Administration approval of brentuximab vedotin (Adcetris
®
), a 
conjugate between a monoclonal antibody that targets the cell-membrane protein CD30, an antigen 
which is highly expressed in lymphoid tumors, and several units of the potent antimitotic agent 
monomethyl auristatin E, a synthetic analog of the marine compound dolastatin 10 [237]. 
This review aims to continue contributing to the marine preclinical pipeline review series that was 
initiated in 1998 [1–7] and reveals the breadth of preclinical pharmacological research during  
2009–2011, resulting from the global research effort of chemists and pharmacologists from Australia, 
Belgium, Brazil, Canada, China, Colombia, Cuba, Egypt, Fiji, France, Germany, Indonesia, Israel, 
Italy, Japan, Luxemburg, Malaysia, Mexico, the Netherlands, New Caledonia, New Zealand, Norway, 
Panama, Papua New Guinea, Philippines, South Africa, South Korea, Singapore, Spain, Switzerland, 
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Taiwan, Thailand, United Kingdom, Venezuela, Vietnam, and the United States. Thus, we feel 
confident to predict that the marine preclinical pharmaceutical pipeline will most probably continue to 
provide novel pharmacological lead compounds that will enrich the marine clinical pharmaceutical 
pipeline [200], which currently consists of 6 U.S. Food and Drug Administration-approved 
pharmaceuticals and 11 compounds in Phase I, II and III of clinical development and which may be 
viewed at [238]. 
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